« Return to News | Drug Sponsors

Celtaxsys restructures, enhances operational focus

Monday, September 16, 2013 08:43 AM

Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.

Dr. Michael Hanley has retired as chief executive officer and chairman, and Dr. Brett Premack has stepped down as chief technology officer. Dr. H. Daniel Perez, a member of the Celtaxsys board and former chief executive officer of Berlex Biosciences and Presidio Pharmaceuticals, is serving as chairman.

Ed Philpot, M.D., now is chief medical officer. Philpot has been chair of the medical advisory panel for the CTX-4430 development program for the past year and was formerly chief medical officer at Smith & Nephew and previously executive director of pulmonary disease and immuno-inflammation at GlaxoSmithKline, where he led several late stage clinical development programs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.